3.93
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - Reuters
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com Canada
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com
Published on: 2025-12-08 04:36:17 - moha.gov.vn
Annovis Bio Inc. (ANVS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Annovis Bio Inc. stock a top hedge fund pickEarnings Beat & High Conviction Buy Zone Picks - Newser
Why institutional investors increase stakes in Annovis Bio Inc. stockEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
Why Annovis Bio Inc. stock fits value portfoliosJuly 2025 Summary & Low Risk High Reward Ideas - Newser
Why Annovis Bio Inc. stock is a must watch tickerEarnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Annovis Bio (ANVS) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
How Annovis Bio Inc. stock compares with top peers2025 Price Targets & Weekly Stock Breakout Alerts - Newser
How geopolitical risks impact Annovis Bio Inc. stockWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga
Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting - citybuzz
Annovis Bio, Inc. to Present At the 2025 Annual Meeting of the Parkinson Study Group - marketscreener.com
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - The Manila Times
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise - MSN
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Certain Warrants of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener
Why analysts remain bullish on Annovis Bio Inc. stock2025 Earnings Impact & Daily Profit Focused Stock Screening - moha.gov.vn
Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock - MarketBeat
Annovis Bio : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Annovis Bio director Hoffman buys $159k in shares By Investing.com - Investing.com Nigeria
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
Annovis Bio director Hoffman buys $159k in shares - Investing.com
Annovis Bio Director Michael B Hoffman Buys 39,200 Shares - TradingView
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MyChesCo
Annovis Announces Two Presentations at the CTAD 2025 Conference - The Manila Times
Annovis Bio (NYSE: ANVS) to share two CTAD 2025 presentations on buntanetap - Stock Titan
Annovis Bio director Hoffman buys $69.9k in ANVS stock By Investing.com - Investing.com Nigeria
Annovis Bio director Hoffman buys $69.9k in ANVS stock - Investing.com
Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS] - TradingView
Will Annovis Bio Inc. stock attract long term capital inflows2025 Short Interest & Intraday High Probability Setup Alerts - newser.com
How Annovis Bio Inc. stock reacts to stronger dollarJuly 2025 Technicals & Long-Term Safe Investment Ideas - newser.com
Annovis Bio Inc Stock Analysis and ForecastDividend Stability Analysis & Small Budget Capital Growth - earlytimes.in
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):